Etoposide-induced apoptosis is not associated with the Fas pathway in acute myeloblastic leukemia cells

Abstract 

Two subclones of the OCI/AML-2 cell line, etoposide-sensitive (ES) and etoposide-resistant (ER), established by the authors, were used as models. We investigated whether the Fas pathway is involved in etoposide-induced apoptosis in acute myeloblastic leukemia (AML). Both of the studied subclones expressed the Fas receptor (FasR), but only the ER cell line expressed the Fas ligand (FasL). Etoposide caused an increase in the mean fluorescence intensity of FasR in both subclones, and an induction of FasL in the ES subclone. However, no change in the numbers of apoptotic cells induced by etoposide was observed when FasR was blocked by an antagonist anti-Fas antibody, nor was an agonist anti-Fas antibody alone cytotoxic to the subclones or enhanced the cytotoxic effect of etoposide. The Fas-resistant phenotype of the AML cells was converted to a Fas-sensitive one by cycloheximide (CHX) suggesting the presence of an inhibitory protein of the Fas pathway in the cells. In etoposide-induced apoptosis, the effect of CHX was different, apoptosis-preventing. In conclusion, etoposide-induced apoptosis is not mediated by the Fas pathway in AML.

Keywords:  Etoposide, Fas, Apoptosis, AML

Abbreviations:  AML, acute myeloblastic leukemia, CHX, cycloheximide, FasL, Fas ligand, FasR, Fas receptor, FBS, fetal bovine serum, FITC, fluorescein iso-thiocyanate-conjugated, α-MEM, α-minimal essential medium, ΔMFI, change in mean fluorescence intensity, PBS, phosphate-buffered saline, PI, propidium iodide, RT-PCR, reverse transcription polymerase chain reaction